2023
Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma
Miguez S, Lee R, Chan A, Demkowicz P, Jones B, Long C, Abramson D, Bosenberg M, Sznol M, Kluger H, Goldbaum M, Francis J, Pointdujour-Lim R, Bakhoum M. Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma. Ophthalmology 2023, 130: 598-607. PMID: 36739981, PMCID: PMC10619207, DOI: 10.1016/j.ophtha.2023.01.020.Peer-Reviewed Original ResearchConceptsMetastasis-free survivalRisk of metastasisClass 2 tumorsAdditional prognostic valueRate of metastasisPrognostic usefulnessTumor sizeTumor characteristicsPrognostic valueUveal melanomaGene expression profile testingMemorial Sloan-Kettering Cancer CenterGEP classificationCox hazard regression analysisYale-New Haven HospitalHazards regression analysisGene expression profiling testsNew Haven HospitalClass 1 tumorsGEP class 2Class 1AMean followTumor thicknessCancer CenterSurveillance protocol
2001
Do HIV Type 1 RNA Levels Provide Additional Prognostic Value to CD4+ T Lymphocyte Counts in Patients with Advanced HIV Type 1 Infection?
Arduino J, Fischl M, Stanley K, Collier A, Spiegelman D. Do HIV Type 1 RNA Levels Provide Additional Prognostic Value to CD4+ T Lymphocyte Counts in Patients with Advanced HIV Type 1 Infection? AIDS Research And Human Retroviruses 2001, 17: 1099-1105. PMID: 11522179, DOI: 10.1089/088922201316912709.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsHIV-1 disease progressionBaseline HIV-1 RNA levelsT-lymphocyte countsT lymphocytesDisease progressionLymphocyte countRNA levelsCells/Prognostic informationHigh baseline HIV-1 RNA levelsHIV type 1 RNA levelsPlasma HIV-1 RNA levelsSubsequent HIV-1 disease progressionAdvanced HIV-1 diseaseHIV Type 1 InfectionConditional logistic regression analysisDisease progression independentHIV-1 diseaseAdditional prognostic informationAdditional prognostic valueType 1 infectionCase-control studyLogistic regression analysisClinical status
2000
Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.
Thor AD, Liu S, Edgerton S, Moore D, Kasowitz KM, Benz CC, Stern DF, DiGiovanna MP. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. Journal Of Clinical Oncology 2000, 18: 3230-9. PMID: 10986055, DOI: 10.1200/jco.2000.18.18.3230.Peer-Reviewed Original ResearchConceptsBreast cancerErbB-2 expressionPrognostic valueErbB-2Node-positive breast cancerNode-positive patientsPositive lymph nodesDisease-specific survivalPrimary breast cancerAdditional prognostic valueInvasive breast cancerNode-positive casesBreast cancer patientsSignificant prognostic valueStudy of incidenceArchival breast cancer samplesErbB-2-positive cellsBreast cancer samplesBreast cancer cellsInvasive breast cancer cellsIdentification of casesLymph nodesPatient groupPoor prognosisCancer patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply